Rostatin Dosage/Direction for Use

Recommended Dose: Doses should be individualized according to the baseline LDL-cholesterol levels, the recommended goal of therapy, and patient response; adjustments should be made at intervals of 2-4 weeks.
Children: 10-17 years (female >1 year postmenarche): HeFH: 5-20 mg once daily; maximum: 20 mg/day.
Adults: Initial dose: General dosing: 10 mg once daily; 20 mg once daily may be used in patients with severe hyperlipidemia (LDL >190 mg/dL) and aggressive lipid targets.
Conservative dosing: Patients requiring less aggressive treatment or predisposed to myopathy (including patients of Asian descent): 5 mg once daily.
Titration: After 2 weeks, may be increased by 5-10 mg once daily; dosing range: 5-40 mg/day (maximum dose: 40 mg once daily).
Note: The 40 mg dose should be reserved for patients who have not achieved goal cholesterol levels on a dose of 20 mg/day, including patients switched from another HMG-CoA reductase inhibitor.
Homozygous familial hypercholesterolemia (FH): Initial: 20 mg once daily (maximum dose: 40 mg/day).
Dosage adjustment with concomitant medications: Cyclosporine: Rosuvastatin dose should not exceed 5 mg/day.
Gemfibrozil: Avoid concurrent use; if unable to avoid concurrent use, rosuvastatin dose should not exceed 10 mg/day.
Atazanavir/ritonavir or lopinavir/ritonavir: Rosuvastatin dose should not exceed 10 mg/day.
Dosage adjustment in renal impairment: Mild to moderate impairment: No dosage adjustment required.
Clcr <30 ml/minute/1.73 m²: Initial: 5 mg/day; do not exceed 10 mg once daily.
Dosage adjustment in hepatic impairment: Active hepatic disease, including unexplained persistent transaminase elevations: Use is contraindicated.
Mode of Administration: May be administered with or without food. May be taken at any time of the day.